Loading...

Steve Swenson, PhD

Title(s)Assistant Professor of Research Neurological Surgery
AddressHMR 2011 Zonal Avenue 813
Off Campus
Los Angeles CA 90089
Phone+1 323 442 5680
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    My main area of scientific interest lies in the development of novel direct acting protein based drugs to be utilized in the fight against disease. This interest has been addressed and will continue to be pursued through three distinct but related studies:
    The development of novel protein based agents, understanding their mechanism of action and effect on disease
    The delivery and efficient targeting of protein based therapeutics characterizing their biochemical and biophysical properties.
    Modification of proteinsand gaining an understanding of their action for use as diagnostic and imaging agents in determination of disease progression.
    My future research plans in the near term involve continued development of the snake venom disintegrin CN as a clinically applicable therapeutic agent both in collaboration with the Markland laboratory and as an independent investigator. In one study, we plan to biochemically, biophysically and biologically evaluate a recombinant version of contortrostatin (rCN) under production in Dr. Marklands laboratory. In addition to the rCN characterization development of assays to assure rCN batch-to-batch production quality and homogeneity are under way.

    It has been observed that binding of CN to integrins produces an effect on a number of cellular processes including cell migration and cell cycle progression. However, the mechanism behind these effects is unknown. Elucidation of the effect of CN on signaling pathways within a cell will enhance our knowledge about cellular processes and may allow for the development of more effective anticancer therapy. In addition to delving into a mechanistic understanding of CN, I am focused on the development of disintegrin based imaging agents which will aid in diagnostics and evaluation of metastatic disease. These studies are possible because CN accumulates at the site of a tumor. By employing PET imaging (Positron Emission Tomography) of a radio-labeled CN in conjunction with 18Ffluorodeoxyglucose (18FDG) utilization, It is planned that an agent will be developed that is capable of identifying and evaluating metastatic tumor foci. Along these same lines I plan to develop a brachytherapeutic to be used in gliomas. CN or other similar proteins can be labeled with a radionuclide such as 131I and administered intrathecally. To act directly on the growing gliomas.

    An additional project will involve screening venoms from different snake families and species to determine the protein composition of the venom (a snake venom proteomics project) in collaboration with Dr. Austin Yang of the USC School of Pharmacy who is interested in such a project. This screening will allow me to identify possible candidate proteins for development into therapeutic agents. All venom is different and understanding what is actually present and what can be used would be a great leap in understanding the biochemistry of venom proteins.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas. PLoS One. 2020; 15(9):e0238238. Minea RO, Duc TC, Swenson SD, Cho HY, Huang M, Hartman H, Hofman FM, Schönthal AH, Chen TC. PMID: 32881880.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    2. NEO100 enables brain delivery of blood-brain barrier-impermeable therapeutics. Neuro Oncol. 2020 Sep 02. Wang W, Marín-Ramos NI, He H, Zeng S, Cho HY, Swenson SD, Zheng L, Epstein AL, Schönthal AH, Hofman FM, Chen L, Chen TC. PMID: 32877532.
      View in: PubMed   Mentions:    Fields:    
    3. Preclinical studies of a novel snake venom-derived recombinant disintegrin with antitumor activity: A review. Biochem Pharmacol. 2020 Jul 12; 114149. Schönthal AH, Swenson SD, Chen TC, Markland FS. PMID: 32663453.
      View in: PubMed   Mentions:    Fields:    
    4. Methods for Evaluation of a Snake Venom-Derived Disintegrin in Animal Models of Human Cancer. Methods Mol Biol. 2020; 2068:185-204. Swenson SD, Silva-Hirschberg C, Markland FS. PMID: 31576529.
      View in: PubMed   Mentions:    Fields:    
    5. Inhibition of motility by NEO100 through the calpain-1/RhoA pathway. J Neurosurg. 2019 Aug 16; 1-12. Marín-Ramos NI, Pérez-Hernández M, Tam A, Swenson SD, Cho HY, Thein TZ, Hofman FM, Chen TC. PMID: 31419797.
      View in: PubMed   Mentions: 1     Fields:    
    6. The Rolipram-Perillyl Alcohol Conjugate (NEO214) Is A Mediator of Cell Death through the Death Receptor Pathway. . 2019 03; 18(3):517-530. Cho HY, Thein TZ, Wang W, Swenson SD, Fayngor RA, Ou M, Marín-Ramos NI, Schönthal AH, Hofman FM, Chen TC. PMID: 30647121.
      View in: PubMed   Mentions:
    7. A Novel Venom-Derived Peptide for Brachytherapy of Glioblastoma: Preclinical Studies in Mice. Molecules. 2018 Nov 08; 23(11). Swenson S, Minea RO, Tuan CD, Thein TZ, Chen TC, Markland FS. PMID: 30413113.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    8. NEO212 Inhibits Migration and Invasion of Glioma Stem Cells. . 2018 03; 17(3):625-637. Marín-Ramos NI, Thein TZ, Cho HY, Swenson SD, Wang W, Schönthal AH, Chen TC, Hofman FM. PMID: 29440289.
      View in: PubMed   Mentions:
    9. Multimeric disintegrin protein polymer fusions that target tumor vasculature. Biomacromolecules. 2014 Jul 14; 15(7):2347-58. Janib SM, Gustafson JA, Minea RO, Swenson SD, Liu S, Pastuszka MK, Lock LL, Cui H, Markland FS, Conti PS, Li Z, MacKay JA. PMID: 24871936.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    10. Snake venom metalloproteinases. Toxicon. 2013 Feb; 62:3-18. Markland FS, Swenson S. PMID: 23000249.
      View in: PubMed   Mentions: 49     Fields:    Translation:Cells
    11. Contortrostatin, a homodimeric disintegrin isolated from snake venom inhibits herpes simplex virus entry and cell fusion. Antivir Ther. 2012; 17(7):1319-26. Hubbard S, Choudhary S, Maus E, Shukla D, Swenson S, Markland FS, Tiwari V. PMID: 22875654.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    12. Development of a chimeric recombinant disintegrin as a cost-effective anti-cancer agent with promising translational potential. Toxicon. 2012 Mar 15; 59(4):472-86. Minea R, Helchowski C, Rubino B, Brodmann K, Swenson S, Markland F. PMID: 21354198.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    13. The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo. Prostate. 2010 Sep 01; 70(12):1359-70. Lin E, Wang Q, Swenson S, Jadvar H, Groshen S, Ye W, Markland FS, Pinski J. PMID: 20623636.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    14. Vicrostatin - an anti-invasive multi-integrin targeting chimeric disintegrin with tumor anti-angiogenic and pro-apoptotic activities. PLoS One. 2010 Jun 03; 5(6):e10929. Minea RO, Helchowski CM, Zidovetzki SJ, Costa FK, Swenson SD, Markland FS. PMID: 20532165.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    15. The use of pepsin in receptor internalization assays. Biochem Biophys Res Commun. 2009 Oct 16; 388(2):240-6. Helchowski CM, Minea RO, Swenson SD, Markland FS. PMID: 19665997.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    16. Integrin agonists as adjuvants in chemotherapy for melanoma. Clin Cancer Res. 2008 Oct 01; 14(19):6193-7. Schwartz MA, McRoberts K, Coyner M, Andarawewa KL, Frierson HF, Sanders JM, Swenson S, Markland F, Conaway MR, Theodorescu D. PMID: 18829498.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    17. Structure of acostatin, a dimeric disintegrin from Southern copperhead (Agkistrodon contortrix contortrix), at 1.7 A resolution. Acta Crystallogr D Biol Crystallogr. 2008 Apr; 64(Pt 4):466-70. Moiseeva N, Bau R, Swenson SD, Markland FS, Choe JY, Liu ZJ, Allaire M. PMID: 18391413.
      View in: PubMed   Mentions: 8     Fields:    Translation:AnimalsCells
    18. Anti-angiogenesis and RGD-containing snake venom disintegrins. Curr Pharm Des. 2007; 13(28):2860-71. Swenson S, Ramu S, Markland FS. PMID: 17979731.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimals
    19. Development of a novel recombinant disintegrin, contortrostatin, as an effective anti-tumor and anti-angiogenic agent. Pathophysiol Haemost Thromb. 2005; 34(4-5):177-83. Minea R, Swenson S, Costa F, Chen TC, Markland FS. PMID: 16707923.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    20. Contortrostatin, a snake venom disintegrin with anti-angiogenic and anti-tumor activity. Pathophysiol Haemost Thromb. 2005; 34(4-5):169-76. Swenson S, Costa F, Ernst W, Fujii G, Markland FS. PMID: 16707922.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    21. Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression. . 2004 Apr; 3(4):499-511. Swenson S, Costa F, Minea R, Sherwin RP, Ernst W, Fujii G, Yang D, Markland FS. PMID: 15078994.
      View in: PubMed   Mentions:
    22. Purification, crystallization and preliminary X-ray analysis of the disintegrin contortrostatin from Agkistrodon contortrix contortrix snake venom. Acta Crystallogr D Biol Crystallogr. 2002 Dec; 58(Pt 12):2122-4. Moiseeva N, Swenson SD, Markland FS, Bau R. PMID: 12454474.
      View in: PubMed   Mentions: 2     Fields:    Translation:Cells
    23. Molecular cloning and functional expression of contortrostatin, a homodimeric disintegrin from southern copperhead snake venom. Arch Biochem Biophys. 2000 Mar 15; 375(2):278-88. Zhou Q, Hu P, Ritter MR, Swenson SD, Argounova S, Epstein AL, Markland FS. PMID: 10700384.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    24. Contortrostatin, a homodimeric disintegrin, binds to integrin alphavbeta5. Biochem Biophys Res Commun. 2000 Jan 07; 267(1):350-5. Zhou Q, Nakada MT, Brooks PC, Swenson SD, Ritter MR, Argounova S, Arnold C, Markland FS. PMID: 10623623.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    Stephen's Networks
    Concepts (153)
    Derived automatically from this person's publications.
    _
    Co-Authors (9)
    People in Profiles who have published with this person.
    _
    Similar People (59)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _